Cited by 2,609Pancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsCancer-related Molecular Pathways

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice

Open access
Hingorani, Sunil R., Wang, Lifu, Multani, Asha S., Combs, Chelsea, Deramaudt, Therese B., Hruban, Ralph H., Rustgi, Anil K., Chang, Sandy +1 more·2005·Cancer Cell

Abstract

To define the genetic requirements for pancreatic ductal adenocarcinoma (PDA), we have targeted concomitant endogenous expression of Trp53(R172H) and Kras(G12D) to the mouse pancreas, revealing the cooperative development of invasive and widely metastatic carcinoma that recapitulates the human disease. The primary carcinomas and metastases demonstrate a high degree of genomic instability manifested by nonreciprocal translocations without obvious telomere erosion-hallmarks of human carcinomas not typically observed in mice. No mutations were discovered in other cardinal tumor suppressor gene pathways, which, together with previous results, suggests that there are distinct genetic pathways to PDA with different biological behaviors. These findings have clear implications for understanding mechanisms of disease pathogenesis, and for the development of detection and targeted treatment strategies.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2005.04.023

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The Mm1 cell line is derived from a liver metastasis of the autochthonous KPC model of pancreatic cancer, which recapitulates the low immunogenicity and immunotherapy responsiveness of the human pancreatic cancer.

    “which is derived from a liver metastasis of the autochthonous KPC model of pancreatic cancer,73 which recapitulates the low immunogenicity and immunotherapy responsiveness of the human pancreatic cancer.”
  • GEMMs combining Kras mutation with inactivation of Cdkn2a and Tp53, or with inactivation of TGFβ-SMAD4 signaling, develop invasive and metastatic PDAC, validating these tumor suppressor pathways in PDAC progression.

    “GEMMs with compound mutations that combine Kras mutation with the inactivation of tumor suppressor genes Cdkn2a and Tp53, or with the inactivation of the TGFβ-SMAD4 signaling pathway in the pancreas develop invasive and metastatic PDAC (74–76), thus validating the role of these tumor suppressor pathways in PDAC progression (4).”

    From KRAS mutation in pancreatic cancer (2021) · cites this paper as [75]

  • Combined expression of oncogenic Kras with deletion or loss of function of Trp53, Cdkn2a, or Smad4 in mouse pancreas readily leads to invasive PDAC.

    “combined expression of oncogenic Kras coupled with the deletion or loss of function of Trp53, Cdkn2a, or Smad4 in the pancreas of mice readily leads to invasive PDAC29–32.”

    From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [30]

  • Altered p53 function has multiple tumor-promoting effects on neoplastic cells, including increased genomic instability, reprogrammed cellular metabolism, and enhanced metastatic propensity.

    “altered p53 function has a multitude of tumor-promoting effects on neoplastic cells, including increased genomic instability30, reprogrammed cellular metabolism57,58, and enhanced metastatic propensity59.”

    From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [30]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A.
Affiliations
  • Abramson Cancer Center (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • Johns Hopkins University (US)
  • University of Pennsylvania (US)
Corresponding author
  • Hingorani, Sunil R.
  • Tuveson, David A.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2005-05
Volume
7
Issue
5
Pages
469-483
ISSN
1535-6108 (ISSN-L)
OpenAlex
W1992995822
Cited by
2,609
References
61
Citations by year
2026: 128 · 2025: 127 · 2024: 208 · 2023: 213 · 2022: 171 · 2021: 217 · 2020: 180 · 2019: 176 · 2018: 164 · 2017: 151 · 2016: 146 · 2015: 128 · 2014: 112 · 2013: 116 · 2012: 77
FWCI
18.03
Type
journal article
Language
en
Open access
Locations
  • Cancer Cell (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute on Aging (K08AG001019)
  • National Cancer Institute (R25-CA87812, P50CA-62924, U01CA084291, R25CA087812, R01CA101973, P50CA062924)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK60694, R01DK060694)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
pancreatic ductal adenocarcinoma, KRAS G12D, chromosomal instability, non-reciprocal translocation, metastasis, tumor suppressor, oncogene cooperation, mouse model, pancreatic carcinogenesis, genomic instability
MeSH terms
Animals, Chromosome Aberrations, Gene Expression Regulation, Mice, Inbred C57BL, Mice, Inbred Strains, Mice, Mutant Strains, Mice, Transgenic, Neoplasm Metastasis, Translocation, Genetic, Gene Rearrangement, Trans-Activators, Cadherins, Gene Expression, Survival Analysis, Genes, Tumor Suppressor, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), Telomere, Centrosome, Homeodomain Proteins, Disease Progression, ras Proteins, Oncogene Proteins v-erbB, Integrases, Mutation, Missense, Cytogenetic Analysis, Carcinoma, Pancreatic Ductal, Chromosomal Instability, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review